^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRR11 (Proline Rich 11)

    i
    Other names: PRR11, Proline Rich 11, Proline-Rich Protein 11, FLJ11029, Transcription Repressor Of MHCII
    Associations

    News

    Trials
    26d
    Prognostic value and experimental validation of atherosclerosis-derived pathogenic genes in colorectal cancer. (PubMed, Front Oncol)
    A CRC risk model based on 6 AS-related genes was developed, identifying 3 novel AS genes. It highlights shared genetic factors, offering prognostic biomarkers for both diseases and insights into their interconnected mechanisms.
    Journal
    |
    PALB2 (Partner and localizer of BRCA2) • CDC25C (Cell Division Cycle 25C) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • HMMR (Hyaluronan Mediated Motility Receptor) • KPNA2 (Karyopherin Subunit Alpha 2) • PRR11 (Proline Rich 11)
    1m
    PRR11 as a newly identified oncogenic driver in retinoblastoma. (PubMed, Sci China Life Sci)
    These findings establish PRR11 as an oncogenic driver in RB and highlight the OTUB1-PRR11-DKK3 axis as a regulatory mechanism of Wnt/β-catenin signaling in RB tumorigenesis. Targeting PRR11 and its downstream pathways provides a potential and novel therapeutic strategy for RB treatment.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3) • PRR11 (Proline Rich 11)
    3ms
    Overexpressed PRR11-SKA2-miR301a/454 bidirectional transcription unit essentially and coordinately promotes PI3K-AKT pathway activation and lung cancer progression. (PubMed, Oncogene)
    Moreover, the transcription unit presents as a prominent prognostic meta-marker for lung cancer. Collectively, these findings demonstrate the essential and coordinated roles of PRR11-SKA2-miR301a/454 bidirectional transcription unit in lung cancer progression, highlighting its potential diagnostic and therapeutic values in cancers.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • ATP6AP2 (ATPase H+ Transporting Accessory Protein 2) • MIR454 (MicroRNA 454) • PRR11 (Proline Rich 11)
    10ms
    A comprehensive review and in silico analysis of the role of survivin (BIRC5) in hepatocellular carcinoma hallmarks: A step toward precision. (PubMed, Int J Biol Macromol)
    We evaluated its potential as a diagnostic, prognostic, predictive, and pharmacodynamic biomarker in HCC, emphasizing its relevance in precision medicine. Finally, we summarized emerging survivin-targeted therapeutics and ongoing clinical trials, underscoring the need for novel strategies to effectively target survivin in HCC.
    Review • Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • PLK1 (Polo Like Kinase 1) • CDCA3 (Cell Division Cycle Associated 3) • FOXM1 (Forkhead Box M1) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CCNB2 (Cyclin B2) • KIF11 (Kinesin Family Member 11) • CCNB1 (Cyclin B1) • CDC45 (Cell Division Cycle 45) • CENPA (Centromere protein A) • CEP55 (Centrosomal Protein 55) • KIF2C (Kinesin Family Member 2C) • KPNA2 (Karyopherin Subunit Alpha 2) • PRR11 (Proline Rich 11) • GTSE1 (G2 And S-Phase Expressed 1)
    12ms
    FBXW7/GSK3β-mediated proline-rich 11 degradation promotes oxidative DNA damage and inhibits tumor progression in renal cell carcinoma. (PubMed, Theranostics)
    The FBXW7/GSK3β-PRR11-AKT axis plays a pivotal role in the development of RCC by regulating oxidative DNA damage. Targeting PRR11 may be a potential therapeutic strategy for RCC.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • PRR11 (Proline Rich 11)
    12ms
    PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S Progression and Epithelial-Mesenchymal Transition. (PubMed, Cancer Med)
    Our study demonstrates that silencing PRR11 can arrest the malignant progression of bladder cancer by inhibiting EMT and blocking the G1/S transition. Targeting PRR11 may provide new insights for targeting cell cycle therapy.
    Journal
    |
    PRR11 (Proline Rich 11)
    1year
    Screening for proline‑rich protein 11 gene expression in cervical cancer: Use as a novel diagnostic biomarker and poor prognostic factor. (PubMed, Med Int (Lond))
    Thus, PRR11 satisfies the standard criteria to be applied in diagnosis. On the whole, the present study demonstrates that PRR11 is well-expressed in cervical cancer tissues, is related to age and a poor prognosis, and may thus serve as a potential novel biomarker for cervical cancer diagnosis.
    Journal
    |
    ATP6AP2 (ATPase H+ Transporting Accessory Protein 2) • PRR11 (Proline Rich 11)
    over1year
    Personalized treatment of perihilar cholangiocarcinoma based on tumor genetic and molecular characteristics. (PubMed, World J Gastrointest Surg)
    Personalized treatment approaches offer new opportunities for effectively targeting the underlying drivers of tumor growth and progression. The findings based on tumor genetic and molecular characteristics highlight the importance of developing personalized treatment strategies.
    Journal
    |
    PKM (Pyruvate Kinase M1/2) • PRR11 (Proline Rich 11) • TCF7 (Transcription Factor 7)
    over1year
    Impact of PRR11 Expression on Prognosis in Pancreatic Cancer Patients with Diabetes. (PubMed, Altern Ther Health Med)
    It suggests that PRR11 may play a role in the occurrence and development of pancreatic cancer and could serve as a potential predictive marker and therapeutic target. However, further research is warranted to explore the functional mechanisms and pathways of PRR11 to better understand its role in pancreatic cancer, and develop personalized therapies.
    Journal
    |
    ATP6AP2 (ATPase H+ Transporting Accessory Protein 2) • PRR11 (Proline Rich 11)
    over1year
    A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma. (PubMed, Redox Biol)
    Importantly, downregulated PRR11 increases lipid peroxidation and alters DHODH-mediated mitochondrial morphology, thereby promoting ferroptosis and increasing TMZ chemotherapy sensitivity. In conclusion, our results reveal a mechanism via which PRR11 drives ferroptosis resistance and identifies ferroptosis induction and TMZ as an attractive combined therapeutic strategy for GBM.
    Journal
    |
    PRR11 (Proline Rich 11)
    |
    temozolomide
    almost2years
    Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target. (PubMed, J Cell Mol Med)
    The involvement of hsa-miR-200b-3p in the regulation of SPDL1 expression by PRR11 was also highlighted. Overall, the study elucidates that PRR11 modulates patient immunotherapy by influencing PDL1 expression through its interaction with SPDL1, with potential upstream regulation by hsa-miR-200b-3p.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MIR200B (MicroRNA 200b) • PRR11 (Proline Rich 11)
    |
    PD-L1 expression
    almost2years
    Prognostic value of PRR11 and immune cell infiltration in Ewing sarcoma. (PubMed, PLoS One)
    PRR11 and mast cell infiltration are potential prognostic indicators in ES. PRR11 possibly affects the prognosis of patients with ES through the cell cycle pathway.
    Journal • Immune cell
    |
    PRR11 (Proline Rich 11)